Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple iodine solution make thyroid surgery safer?

NCT ID NCT04856488

Disease control Sponsor: Jan Calissendorff Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving Lugol's solution before removing the thyroid gland can lower the chance of two common surgery complications: low calcium levels from damaged parathyroid glands and vocal cord weakness from nerve injury. About 182 adults with overactive thyroid from Graves' disease or toxic nodular goiter will take part. The goal is to make surgery safer and reduce the need for long-term calcium or vitamin D supplements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 182 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4 \<30 pmol/L or Graves' disease * Signed informed consent Exclusion Criteria: * Unstable coronary artery disease * Previous thyroid surgery * Congestive heart failure * Renal insufficiency * Hepatic failure * Current infection * Treatment with steroids or anticoagulants * Thyroid associated orbitopathy CAS \> 2 * Diabetes mellitus type 1 * Active cancer * Severe psychiatric illness * Amiodarone treatment * Pregnancy * Breast feeding * Women of child bearing potential not using contraceptive * Inability to comprehend the meaning of the study * Iodine hypersensitivity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Graves disease hyperthyroidism toxic multinodular goitre

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperthyroidism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Endocrinology, Karolinska University Hospital

    RECRUITING

    Solna, Stockholm County, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.